Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study.
Launched by EUROPEAN LUNG CANCER WORKING PARTY · Sep 24, 2008
Trial Information
Current as of August 02, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Pathologically demonstrated NSCLC
- • Stage I-III treated by curative treatment by surgery with or without chemotherapy (induction or adjuvant) or by chemoradiotherapy
- • Inoperable patients treated by exclusive radiotherapy
- • A whole-body (skull base to mid thighs) FDG-PET or a combined FDG-PET/CT on a dedicated machine, performed before any anticancer treatment
- • FDG-PET or combined FDG-PET/CT has to be previously standardised according to the procedure described in appendix IV
- • Written informed consent
- • Accessibility to follow-up
- • Age \> 18 years
- Exclusion Criteria:
- • Prior anticancer treatment (surgery, radiotherapy or chemotherapy)
- • Stage IV NSCLC
- • A history of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix and cured malignant tumour (more than 5-year disease free interval)
- • Uncontrolled diabetes mellitus (fast glycaemia above 130 mg/dl)
- • Pregnancy and lactating woman
- • Unavailability to send a copy of the PET or PET-CT (DICOM format) to the data centre
About European Lung Cancer Working Party
The European Lung Cancer Working Party (ELCWP) is a leading collaborative organization dedicated to advancing research and treatment in lung cancer across Europe. Comprising a network of multidisciplinary experts, ELCWP focuses on conducting innovative clinical trials, fostering international cooperation, and promoting best practices in lung cancer management. By integrating clinical expertise and patient-centered approaches, ELCWP aims to enhance therapeutic outcomes and improve the quality of care for lung cancer patients, ultimately contributing to the global fight against this prevalent disease.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brussels, , Belgium
Ath, , Belgium
Gilly, , Belgium
Mons, , Belgium
Mouscron, , Belgium
Charleroi, , Belgium
Patients applied
Trial Officials
Thierry Berghmans, MD
Study Chair
European Lung Cancer Working Party
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials